AstraZeneca Reaches Obesity Drug Deal; Imfinzi Combination Meets Main Goal In Liver Cancer Trial
9/11 09:35
(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Eccogene have reached an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions...